SWP
VRNA

Stratos Wealth Partners’s Verona Pharma VRNA Stock Holding History

Stratos Wealth Partners’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,540
Closed -$232K – 1234
2023
Q1 		$232K Sell
11,540
-6,820
-37% -$147K 0.01% 981
2022
Q4 		$480K Buy
+18,360
New +$244K 0.01% 749

Other funds holding VRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Stratos Wealth Partners's VRNA Position: Q2 2023 in Review

Stratos Wealth Partners sold out of Verona Pharma (VRNA) in Q2 2023, closing a stake of 11,540 shares — an estimated $232K sold.

Stratos Wealth Partners first reported a position in VRNA in Q4 2022 and held it in 2 quarters. The position peaked at $480K in Q4 2022. 105 funds tracked by Wall St. Rank hold VRNA as of Q2 2023.

  • Stratos Wealth Partners reported no remaining Verona Pharma position as of Q2 2023 after selling out during the quarter.
  • Stratos Wealth Partners sold 11,540 Verona Pharma shares in Q2 2023, an estimated $232K.
  • Stratos Wealth Partners first reported a position in Verona Pharma in Q4 2022 and held it in 2 quarters.
  • Stratos Wealth Partners's Verona Pharma position peaked at $480K in Q4 2022.
  • 105 funds tracked by Wall St. Rank held Verona Pharma as of Q2 2023.

Based on Stratos Wealth Partners's 13F filing for Q2 2023, filed 18 Jul 2023.